Latin American pharmaceutical companies are beginning to treat high-quality scientific data and AI tools as strategic investments rather than operational expenses, a shift that could reshape regional drug discovery and help local firms compete globally. According to CAS, a division of the American Chemical Society, this transformation is critical for the region to match innovation benchmarks in North America, Europe, and Asia.

What's Driving the Change in How Latin America Approaches Drug Discovery?

For decades, smaller pharmaceutical firms across Latin America relied primarily on open or public scientific sources to fuel their research pipelines. This approach kept costs low but limited access to the curated, high-integrity datasets that larger multinational companies use to accelerate development. The perception of data as an operational expense rather than a growth engine has begun to shift, particularly as AI and machine learning tools become more accessible and demonstrate measurable returns on investment.

The region is also seeing regulatory progress that supports this transition. Over the past decade, key health authorities including Mexico's COFEPRIS and Brazil's ANVISA have adopted regulatory reliance mechanisms, allowing them to leverage assessments from trusted authorities and streamline approval processes while maintaining oversight of safety, quality, and efficacy. This convergence creates a more predictable environment for companies investing in advanced research infrastructure.

Patent filings by Mexican residents reached 1,172 domestic applications in 2024, representing a 19.8% increase from the previous year, according to the World Intellectual Property Organization (WIPO). This surge in intellectual property protection reflects growing private investment in innovation across the region.

How Are AI and Curated Data Accelerating Drug Discovery Timelines?

The integration of AI and machine learning is fundamentally reshaping how pharmaceutical research teams work. Traditionally, researchers accessed scientific literature and patent data through web-based platforms, then manually reviewed findings to identify promising drug candidates. Now, enterprise clients are licensing structured, machine-readable datasets directly and integrating them into their proprietary internal systems to run custom AI and predictive models.

This workflow allows research teams to bypass time-consuming manual literature reviews and query target properties directly, generating real-time predictive insights. Bringing a new drug to market historically required up to 10 years. Leveraging high-quality data within predictive AI models can significantly compress these development cycles, though the exact timeline reduction varies by therapeutic area and drug complexity.

The value of human-curated, high-integrity scientific data has become even more vital in this new workflow. Machine learning models require rigorous input data to produce accurate predictions; poor-quality data leads to unreliable results, regardless of how sophisticated the AI algorithm is.

Steps to Building Regional Competitiveness in AI-Driven Drug Discovery

• Adopt Data Quality Standards: Local organizations must invest in the same high-integrity data platforms and standards used by companies in North America, Europe, and Asia to remain competitive on a global scale.
• Shift Organizational Mindset: Changing the perception of scientific data from an operational cost to a strategic growth asset requires ongoing educational efforts across pharmaceutical companies, research institutions, and government bodies.
• Tailor Solutions to Regional Needs: Rather than relying solely on global portfolios brought in by multinational firms, Latin American organizations must develop solutions specifically designed to address regional challenges and opportunities.
• Leverage Regulatory Convergence: Take advantage of strengthened cooperation between regional health authorities to streamline approval processes while maintaining rigorous safety and efficacy standards.

What Commercial Models Are Emerging to Support Diverse Organizations?

CAS has expanded its direct footprint in Latin America significantly over the past decade, transitioning from a single-person presence to a dedicated regional team of 10 professionals serving customers from Mexico to Chile in Spanish and Portuguese. This growth reflects the strategic importance of the region.

The organization operates different business models tailored to three core segments. For academic institutions, partnerships operate on a cost-recovery basis to support platform maintenance and data curation without profit margins. For commercial enterprises and government bodies, CAS functions as a professional services and data partner, with pricing structures that account for organizational scale, research maturity, and local macroeconomic conditions.

"By establishing market-adjusted tiers for emerging markets, we ensure that early-stage ventures, scientific startups, and established institutions alike can access our full scope of curated data and analytic platforms to advance their research pipeline," explained a CAS representative in an interview about the organization's regional strategy.

CAS, American Chemical Society

This tiered approach recognizes that Latin American markets are economically diverse. A one-size-fits-all model does not work across the region; instead, commercial strategies must reflect local macroeconomic conditions and organizational maturity levels to ensure scalable access to scientific data platforms for research teams of all sizes.

How Is CAS Supporting Biodiversity and Indigenous Knowledge Protection?

Supporting natural product research in Latin America involves navigating complex, country-specific intellectual property and legal frameworks. Regulations regarding what can be patented or protected in relation to indigenous natural knowledge vary significantly by jurisdiction. CAS maintains comprehensive databases that help organizations research and protect novel molecules and formulations derived from biodiversity.

However, commercialization and protection strategies must navigate distinct national laws. While certain countries enforce strict regulations around ownership and patent eligibility for local biological assets, others offer clearer mechanisms for protecting derived scientific innovations. CAS works closely with regional research groups exploring biodiversity to provide the data required to validate and protect their formulations within their respective regulatory frameworks.

This support reflects a broader recognition that Latin America possesses unique biological resources and scientific talent that, when paired with modern data infrastructure and AI tools, can generate breakthrough discoveries tailored to regional health needs and global markets.